evipedia.ai
← Back

Nicotinamide Riboside for Health & Longevity

Evidence Review created on 10/14/2026 using AI4L / Opus 5.5

Also known as: NR, Nicotinamide Riboside Chloride, NRC, Niagen, Tru Niagen, Nicotinamide Riboside Malate

Motivation

Nicotinamide riboside (NR) is a form of vitamin B3 present in trace amounts in milk and sold as a dietary supplement. The body converts it into a molecule that every cell needs to turn food into energy and to repair its genetic material. Because levels of that molecule are thought to decline with age, NR has become one of the most widely marketed supplements aimed at healthy aging.

Interest grew from laboratory work asking whether topping up this molecule could slow age-related decline in muscle, metabolism and the brain. That question prompted a wave of human studies, many of them supplied or paid for by the companies that sell NR, in healthy older adults and in people living with age-related conditions.

This review examines the human evidence on NR for health and longevity: which benefits have been tested in controlled trials, which risks and open questions have emerged, how the supplement is typically dosed and monitored, and how the funding of the research shapes what is known.

Benefits - Risks - Protocol - Conclusion

Expert commentary and critical reviews that give a high-level overview of NR and the debate over raising levels of NAD+ (nicotinamide adenine dinucleotide, a molecule cells need for energy production and DNA repair).

Andrew Huberman’s only NR-specific episode (AMA #12) is restricted to paying members, and his free episode on NAD boosters features Peter Attia, whose own article is listed above (one item per expert). Chris Kresser’s site has no dedicated NR content: a 2020 nutrition-and-aging article mentions NR only in passing, and the other search results are broad aging interviews, so none discusses NR in enough depth to be listed.

Grokipedia

  • Nicotinamide riboside

    AI-generated encyclopedia entry covering NR chemistry, conversion to NAD+, clinical studies, commercialization and regulatory status; useful orientation, but claims require checking against primary trials.

Examine

  • Nicotinamide Riboside

    Independent, sponsor-free evidence page (updated August 2025) introducing NR as a vitamin B3 form promoted for healthy aging, with a human-trial research feed; its analysis of effects, dosing and side effects requires a subscription.

ConsumerLab

Systematic Reviews

Systematic reviews and meta-analyses that include human trials of NR, alone or with other NAD+ precursors.

No systematic review or meta-analysis has assessed the harms of NR specifically; the last entry covers harms across all NAD+ precursors.

Mechanism of Action

NR is converted inside cells into NAD+. The enzymes NRK1 and NRK2 (nicotinamide riboside kinases, which attach a phosphate group) turn NR into NMN, which is then assembled into NAD+. NAD+ carries energy in mitochondria (the cell’s power plants) and is consumed by sirtuins (enzymes that use NAD+ to switch genes and proteins on or off), PARPs (DNA-repair enzymes) and CD38 (an immune-cell enzyme that breaks NAD+ down). The rationale: rising consumption lowers NAD+ with age, and restoring it supports mitochondrial function, DNA repair and lower inflammation.

Competing explanations exist. Isotope tracing (tracking labeled molecules) in mice showed that oral NR is metabolized to nicotinamide in the liver, so tissues may receive mainly nicotinamide (Liu et al., 2018). A Nestlé-funded human study proposed that gut bacteria convert NR into nicotinic acid, which then raises blood NAD+ (Christen et al., 2026). Others warn that extra NAD+ can also fuel inflammatory secretions from senescent (permanently arrested) cells (Nacarelli et al., 2019).

  • Half-life: not established for intact NR in humans; blood NAD+ plateaus after about two weeks and falls as slowly after stopping (Berven et al., 2026).
  • Selectivity: none; NR feeds the general NAD+ pool rather than a receptor.
  • Tissue distribution: raises NAD+ in blood (Conze; ChromaDex-run), NAD+-related metabolites in muscle (Elhassan; ChromaDex-supplied), and NAD+ in brain (Nanga et al., 2024).
  • Metabolism: broken down to nicotinamide, then methylated by NNMT (nicotinamide N-methyltransferase, an enzyme that consumes methyl groups) and excreted; no known role for liver CYP (cytochrome P450 drug-metabolizing) enzymes.

Historical Context & Evolution

NR was first described in the 1940s as a growth factor required by the bacterium Haemophilus influenzae, not as a human nutrient. In 2004 Charles Brenner’s laboratory showed that yeast and human cells use NR through a dedicated kinase route, establishing it as a vitamin B3 form (Bieganowski & Brenner, 2004). A mouse study reporting protection against diet-induced obesity (Cantó et al., 2012) and a report of modestly longer life in old mice (Zhang et al., 2016) moved NR into the longevity spotlight. ChromaDex commercialized it as Niagen; Brenner, who has declared holding ChromaDex stock, co-authored the first human pharmacokinetic study (how the body absorbs and clears a substance), with ChromaDex staff as co-authors (Trammell et al., 2016).

The US Food and Drug Administration (FDA) issued a no-questions letter on ChromaDex’s GRAS (generally recognized as safe) notice in 2016 (GRAS Notice No. GRN 000635), and the European Union (EU) authorized NR chloride as a novel food in 2020 (Commission Implementing Regulation (EU) 2020/16). Randomized trials from 2018 onward, mostly using ChromaDex-supplied NR, consistently showed higher blood NAD+ and good tolerability (Martens; Conze).

Opinion shifted as new evidence arrived on both sides. The Interventions Testing Program, a multi-site mouse lifespan program, found no lifespan extension (Harrison et al., 2021); a 2023 critical review found few clinically relevant human effects (Damgaard & Treebak, 2023); and a 2026 phase 3 Parkinson’s trial reversed earlier optimism (Brakedal et al., 2026). Single-trial signals, such as longer walking distance in leg-artery disease (McDermott, ChromaDex-supplied), await replication.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint or validated surrogate has improved with NR in trials from more than one independent research group.

Medium 🟩 🟩

Rare premature-aging and DNA-repair disorders ⭕️ Not Central to Health & Longevity

In Werner syndrome (inherited premature aging), a nine-patient crossover trial (each person took NR and placebo in turn; Shoji, Chiba; ChromaDex-supplied) found less arterial stiffness and smaller skin ulcers; an uncontrolled ataxia-telangiectasia (DNA-repair disorder) study (Veenhuis, Nijmegen) reported better coordination. These bear on rare inherited diseases, not healthy aging.

Magnitude: Cardio-ankle vascular index (an arterial-stiffness measure) changed −0.4 during NR versus +0.9 during placebo (right leg), a statistically significant difference (Shoji et al., 2025); ataxia data are from Veenhuis et al., 2021 (no control group).

Low 🟩

Walking capacity and physical function ⚠️ Conflicted

In the 90-person NICE trial (McDermott, Northwestern; NR donated by ChromaDex), 1 g/day NR lengthened walking distance versus placebo in peripheral artery disease (narrowed leg arteries). A meta-analysis found no muscle-function gain after 60 (Prokopidis); exercise capacity in kidney disease was unchanged (Ahmadi). Net: one positive trial, unreplicated.

Magnitude: 17.6 m farther than placebo on the six-minute walk at six months (90% CI, or confidence interval, the plausible range of the true effect: 1.8 to ∞) (McDermott et al., 2024).

Blood pressure ⚠️ Conflicted

In healthy adults aged 55–79 (Martens, Colorado), NR tended to lower systolic pressure, mostly with elevated readings, but not after statistical correction. Later trials found no benefit alongside exercise (Lin, Alabama) or in memory impairment (Martens, Delaware). Net: unconfirmed.

Magnitude: Systolic pressure 3.9 mmHg lower than placebo after six weeks (one-sided 95% CI −∞ to −0.06), not significant after correction for testing many outcomes (Martens et al., 2018).

Cognition, fatigue and mood ⚠️ Conflicted

Rodent data prompted trials in mild cognitive impairment (memory decline short of dementia; Orr, Wake Forest; Martens, Delaware) and long COVID (Wu, Massachusetts General; funded partly by NR maker Niagen Bioscience). None beat placebo; gains appeared only within groups. Net: controlled evidence is null.

Magnitude: Versus placebo after 10 weeks at 2 g/day, Everyday Cognition score difference 0.08 (95% CI −0.16 to 0.33) and Fatigue Severity Scale difference −1.45 points (95% CI −6.76 to 3.86), neither significant (Wu et al., 2025).

Metabolic health in obesity ⚠️ Conflicted

NR prevented diet-induced obesity in mice (Cantó), but trials in adults with obesity (Dollerup, Aarhus; Remie, Maastricht; Lapatto, Helsinki) found no gain in insulin sensitivity, liver fat or adiposity. One crossover trial reported slightly more lean mass. Net: no meaningful metabolic benefit.

Magnitude: Insulin sensitivity unchanged versus placebo after 12 weeks at 2 g/day (Dollerup et al., 2018); fat-free mass 1.34 percentage points higher than placebo after six weeks at 1 g/day (Remie et al., 2020).

Parkinson’s disease progression ⚠️ Conflicted

In the 30-patient NADPARK trial (Brakedal, Bergen), NR raised brain NAD+ with mild clinical improvement. The same group’s 410-patient phase 3 NOPARK trial then found faster worsening than placebo over 52 weeks. Net: the larger trial does not support benefit.

Magnitude: Symptom score 2.72 points worse than placebo at 52 weeks (95% CI 0.47–4.98) (Brakedal et al., 2026); the earlier pilot is at Brakedal et al., 2022.

Speculative 🟨

Higher NAD+ in blood, muscle and brain ⚠️ Conflicted

Controlled trials show NR raises blood NAD+ (Conze); an uncontrolled study found higher brain NAD+ (Nanga); muscle showed NAD+-related metabolites (Elhassan) but no NAD+ rise in NICE (McDermott). Net: absorption shown; health benefit unproven.

Lower inflammatory markers ⚠️ Conflicted

NR lowered blood cytokines (immune signals; Elhassan) and airway interleukin-8 in chronic lung disease (Norheim et al., 2024; Elysium Health co-authors), not obesity-related inflammation (Remie). Net: inconsistent, unvalidated markers.

Younger epigenetic age

Exploratory analyses in memory-impairment (Orr et al., 2024) and lung-disease trials reported lower epigenetic age (biological age estimated from chemical marks on DNA). These clocks are unvalidated for interventions.

Lifespan extension ⚠️ Conflicted

NR modestly extended life in old mice (Zhang, Lausanne), but the multi-site Interventions Testing Program found no effect (Harrison). No human lifespan data exist. Net: animal evidence leans negative.

Benefit-Modifying Factors

  • Baseline NAD+ status: NAD+ responses vary widely between individuals (Berven et al., 2026), and no trial has tested whether low starting NAD+ predicts benefit; clearer signals have come from NAD+-depleted states such as Werner syndrome (Shoji et al., 2025) than from healthy adults.
  • Baseline blood pressure: the exploratory systolic drop appeared in participants with readings of 120–139 mmHg, not in those with normal pressure (Martens, 2018).
  • Genetic polymorphisms: no variant has been shown to modify NR’s benefits; variants in NNMT or in NMRK1/NMRK2 (genes for the NR-converting kinases) are plausible but untested modifiers.
  • Sex: blood and brain NAD+ responses did not differ by sex (Berven et al., 2026); no trial has reported sex-specific clinical benefits.
  • Pre-existing conditions: benefit signals came from diseased groups (leg-artery disease, chronic lung disease, Werner syndrome); healthy, metabolically fit adults show the fewest effects, and in Parkinson’s disease the largest trial pointed to harm.
  • Age: most trials enrolled adults aged 55–80; in older adults with memory impairment, NR produced no cognitive or walking-speed gains (Orr, 2024), and data beyond 80 are sparse.
  • Adherence: in the NICE trial, the walking gain versus placebo was larger among participants taking at least 75% of capsules (31.0 m) than in all participants (17.6 m) (McDermott et al., 2024).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse clinical outcome has been documented in trials from more than one independent research group.

Medium 🟥 🟥

Faster Parkinson’s disease progression ⚠️ Conflicted

In the phase 3 NOPARK trial (Brakedal and Tzoulis, Bergen; 410 patients with early Parkinson’s disease, 1 g/day for 52 weeks), NR worsened scores on the MDS-UPDRS (the standard Parkinson’s rating scale) and non-motor symptoms more than placebo, though by less than the clinically important threshold. Serious adverse events were less frequent with NR. The same group’s smaller, shorter NADPARK (Brakedal) and NR-SAFE (Berven) trials had suggested mild improvement. Net: the largest, longest trial indicates modest harm in Parkinson’s disease, with no comparable data in people without it.

Magnitude: MDS-UPDRS 2.72 points worse than placebo at 52 weeks (95% CI 0.47–4.98); serious adverse events 8.3% with NR versus 14.1% with placebo (Brakedal et al., 2026).

Low 🟥

Gastrointestinal upset and reduced tolerability ⚠️ Conflicted

Diarrhea was more frequent with NR than placebo in the NICE trial (McDermott), and dropout was higher in an NR-first long-COVID arm (Wu). Safety trials (Conze, ChromaDex-run; Martens) found adverse events similar to placebo. Net: mild, inconsistent effects.

Magnitude: Diarrhea 39.3% with NR versus 27.6% with placebo; nausea 14.3% versus 24.1% (McDermott et al., 2024); no difference from placebo in adverse events at 100–1,000 mg/day (Conze et al., 2019).

Cardiovascular risk from vitamin B3 breakdown products

NR raised plasma 4PY (an end product of excess vitamin B3) (Shoji). In cardiac cohorts, higher 4PY predicted major cardiac events and promoted vessel inflammation in mice (Ferrell). Evidence is indirect: it concerns a metabolite, and no NR trial has measured cardiac events.

Magnitude: Adjusted hazard ratio (relative risk over time) 1.89 (95% CI 1.26–2.84) for three-year major cardiac events with serum 4PY in a US cohort; no NR-specific figure exists (Ferrell et al., 2024).

Higher blood sugar ⚠️ Conflicted

Pooled controlled trials of NAD+ precursors found small rises in fasting glucose and HbA1c, largest with nicotinic acid (Sohouli); this is indirect, as no NR-specific estimate was reported. NR trials in men with obesity found no change in glucose or insulin (Dollerup). Net: unconfirmed for NR.

Magnitude: Fasting glucose 2.17 mg/dL higher (95% CI 0.68–3.66) and HbA1c 0.11 higher (95% CI 0.06–0.16) than control across all NAD+ precursors; no NR-specific figure exists (Sohouli et al., 2024).

Speculative 🟨

Faster cancer growth

In mice, high-dose NR increased triple-negative (hard-to-treat) breast cancer and its spread to the brain (Maric et al., 2023); cell studies link NAD+ to tumor-promoting senescent-cell secretions (Nacarelli). No human data exist.

Methyl-group drain and homocysteine rise ⚠️ Conflicted

Clearing NR’s nicotinamide uses methyl groups. At 3 g/day homocysteine (a vascular-risk amino acid) rose slightly, methyl stores intact (Berven et al., 2023); 1 g/day left methyl metabolism unchanged (Conze). Net: minor, dose-dependent.

Risk-Modifying Factors

  • Parkinson’s disease: people with early Parkinson’s disease worsened more on NR than on placebo over one year (Brakedal et al., 2026); this is the clearest population-specific risk identified.
  • Cancer history: mouse data showing more breast-cancer metastasis (Maric et al., 2023) make active or recent cancer a theoretical risk modifier; no human data exist.
  • Genetic polymorphisms: MTHFR variants (reduced activity of a folate-recycling enzyme) may lower methylation reserve; the variant rs10496731 is associated with levels of 2PY and 4PY (vitamin B3 end products; Ferrell, 2024). Neither has been tested with NR.
  • Baseline homocysteine and B-vitamin status: those starting with high homocysteine or low folate or B12 have less buffer against NR’s methyl-group demand, a theoretical concern at gram doses.
  • Sex: NAD+ responses did not differ by sex (Berven, 2026); in Werner syndrome, liver-enzyme rises during NR occurred only in women (Shoji, 2025); the EU limit is lower (230 mg/day) in pregnancy and lactation (Regulation (EU) 2020/16).
  • Age: trials enrolled adults up to about 80 without excess adverse events; frail adults over 80 are largely unstudied.
  • Kidney and liver function: eGFR (estimated glomerular filtration rate, a kidney-function measure) was unchanged at 1 g/day in chronic kidney disease (Ahmadi et al., 2023); AST and ALT (liver enzymes) trended upward in Werner syndrome (Shoji, 2025).

Key Interactions & Contraindications

No dedicated human drug-interaction study of NR has been published; entries below rely on co-administration trials or mechanism.

Prescription medications

  • Antihypertensives (blood-pressure-lowering drugs: amlodipine, lisinopril, losartan): Monitor (theoretical). If NR’s small exploratory blood-pressure effect is real, additive lowering could cause light-headedness. Home blood-pressure checks during the first weeks address it.
  • PARP inhibitors (olaparib, niraparib): Caution (theoretical). Raising NAD+ could in principle blunt these drugs (cancer treatments that block NAD+-consuming DNA-repair enzymes). Coordination with the treating oncologist is the mitigating step.
  • Chemotherapy and targeted cancer therapy (doxorubicin, investigational inhibitors of NAMPT, the main NAD+-recycling enzyme): Avoid (theoretical). NR bypasses NAMPT (nicotinamide phosphoribosyltransferase) and promoted tumor spread in mice (Maric); consequence is possible reduced treatment efficacy.
  • Glucose-lowering drugs (metformin, insulin): Unlikely (theoretical); untested together. Twelve weeks of 2 g/day NR did not change glucose, insulin or incretin hormones (gut hormones that boost insulin release) in non-diabetic men with obesity (Dollerup et al., 2019), so additive glucose lowering is not expected.
  • Statins (cholesterol-lowering drugs: atorvastatin, rosuvastatin): Unlikely (theoretical); untested together. Unlike nicotinic acid, NR did not raise LDL cholesterol (the artery-clogging “bad” cholesterol) at up to 1 g/day (Conze, 2019); the niacin-statin muscle concern has no NR evidence.

Over-the-counter medications

  • Niacin (nicotinic acid) and nicotinamide products: Monitor (theoretical). Stacking vitamin B3 forms adds to methyl-group demand and 4PY formation; nicotinic acid also causes flushing. Counting total B3 intake mitigates this.
  • Multivitamins and B-complex products: Monitor (theoretical). Their niacin adds to total B3 load; consequence is the same additive methyl and metabolite burden, mitigated by checking labels.

Supplements

  • Nicotinamide mononucleotide (NMN): Monitor (theoretical). Same pathway and additive NAD+ effect, with no evidence that combining improves outcomes; consequence is higher metabolite load and cost.
  • Resveratrol and pterostilbene: Caution for resveratrol; pterostilbene untested (theoretical). In the NICE trial, adding resveratrol gave no extra walking benefit and more diarrhea (54.6% versus 39.3%) and nausea (36.4% versus 14.3%) than NR alone (McDermott et al., 2024).
  • Methyl donors (betaine, folate, vitamin B12): Potentially protective (theoretical). They may offset NR’s methyl-group demand; no trial has tested the pairing, and no harm is expected.
  • Coenzyme Q10: Unlikely (theoretical). Each was given separately in a kidney-disease crossover trial without adverse findings (Ahmadi, 2023); combined use is untested, and no shared pathway predicts harm.

Other interventions

  • Intravenous NAD+ or injectable NR: Monitor (theoretical). Additive NAD+ loading with no safety data for combined oral and injected use; the likely consequence is added methyl-group demand and 4PY formation, as with stacking vitamin B3 forms.
  • Structured exercise: No interaction found. NR added no blood-pressure benefit to supervised walking and caused no excess adverse events (Lin et al., 2025).

Populations who should avoid Nicotinamide Riboside:

  • Parkinson’s disease: Avoid (human data). Early disease, defined in the trial as diagnosis within two years and Hoehn and Yahr stage below 3 (a 1–5 severity scale), worsened with NR (Brakedal et al., 2026).
  • Active cancer or ongoing cancer treatment: Avoid (theoretical), based on mouse metastasis data (Maric et al., 2023).
  • Pregnancy and lactation above 230 mg/day: Avoid; the EU authorization caps intake at 230 mg/day for pregnant and lactating women (Commission Implementing Regulation (EU) 2020/16).
  • Children and adolescents: Avoid; the EU authorization covers adults only (Regulation (EU) 2020/16), and the FDA GRAS notice excludes foods for infants and toddlers (GRN 000635).
  • Known hypersensitivity to NR: Avoid; allergy to NR is an exclusion criterion in NR trials (e.g., NICE-PAD II).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Label-range dosing: keeping intake at or below 300 mg/day, the EU maximum for adults (Regulation (EU) 2020/16), limits exposure to untested long-term effects of gram-level doses.
  • Parkinson’s screening: avoiding NR in diagnosed Parkinson’s disease, and seeking evaluation for new tremor or stiffness, mitigates the faster progression seen in NOPARK (Brakedal et al., 2026).
  • Pausing around cancer: stopping NR during cancer workup or treatment mitigates the theoretical risk of tumor promotion shown in mice (Maric et al., 2023).
  • Homocysteine checks at high doses: at 1 g/day or more, measuring homocysteine at baseline and after 4–8 weeks detects methyl-group drain; a rise above the laboratory range prompts dose reduction or methyl-donor support.
  • Taking with food and splitting doses: taking NR with meals and dividing gram-level doses into two servings reduces diarrhea and nausea.
  • Avoiding B3 stacking: not combining NR with NMN, high-dose niacin or nicotinamide limits methyl-group demand and 4PY formation linked to cardiac risk.
  • Skipping resveratrol combinations: avoiding NR-resveratrol stacks mitigates the extra diarrhea and nausea seen in the NICE trial (McDermott et al., 2024).
  • Blood-pressure checks with antihypertensives: home readings several times weekly for the first month detect additive lowering and light-headedness.
  • Third-party tested products: choosing products with independent testing reduces the risk of underdosing, degradation to nicotinamide or contamination.

Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, titration, cycling) reflect common practice.

  • Label dose: 300 mg/day once daily, the EU maximum for adults (Regulation (EU) 2020/16) and the typical Tru Niagen label serving; popularized by ChromaDex and Charles Brenner.
  • Dose-response range: 100, 300 and 1,000 mg/day raised blood NAD+ by 22%, 51% and 142% in a ChromaDex-run trial (Conze et al., 2019).
  • Trial efficacy dose: 1,000 mg/day (500 mg twice daily) in healthy older adults (Martens et al., 2018) and in Parkinson’s disease (Brakedal et al., 2026); 1,000 mg/day in leg-artery disease (McDermott et al., 2024).
  • High-dose approach: 2,000 mg/day in obesity (Dollerup et al., 2018) and long COVID (Wu et al., 2025); 3,000 mg/day tested for safety (Berven et al., 2023); popularized by Charalampos Tzoulis’s Bergen group for neurological disease.
  • Combination approach: Elysium Health markets NR with pterostilbene; no outcome trial shows it outperforms NR alone, and adding resveratrol showed no advantage in NICE (McDermott et al., 2024).
  • Time of day: no human data favor a time; morning dosing with breakfast is common practice.
  • Half-life: not established for intact NR in humans; blood NAD+ builds over about two weeks and falls slowly after stopping, so daily consistency matters more than timing (Berven et al., 2026).
  • Single versus split dose: with 1.2 g/day given twice daily, the slow NAD+ kinetics led investigators to infer that once-daily dosing would suffice (Berven, 2026); gram-level trials usually split doses twice daily.
  • Titration: some trials escalated from 250 mg to 1,000 mg/day (Lapatto et al., 2023); starting low and increasing over 2–4 weeks is common practice.
  • Genetic polymorphisms: no variant guides dosing; carriers of MTHFR variants using gram doses may pair NR with methyl donors (theoretical).
  • Sex: NAD+ responses do not differ by sex (Berven, 2026), so trials use identical doses for men and women.
  • Age: trials in adults aged 55–80 used the same doses as in younger adults; no age-based adjustment has been defined.
  • Baseline biomarkers: NAD+ responses vary widely between individuals (Berven, 2026), and the rise was larger with lower baseline NAD+ (Martens, 2018); baseline homocysteine helps judge suitability for gram doses.
  • Pre-existing conditions: a heart failure trial used 2 g/day without safety issues (Wang et al., 2022); kidney disease 1 g/day (Ahmadi, 2023); Parkinson’s disease is a reason to avoid NR.

Discontinuation & Cycling

  • Intended duration: used as an ongoing supplement, but no trial has lasted longer than one year (NOPARK, 52 weeks; Brakedal et al., 2026), so lifelong safety is unknown.
  • Withdrawal effects: none reported; blood NAD+ returns toward baseline over weeks after stopping (Berven, 2026). In ataxia telangiectasia, coordination scores worsened again after withdrawal (Veenhuis, 2021).
  • Tapering: not required, as no rebound effects are reported; abrupt stopping is used in trials.
  • Cycling: no evidence supports cycling to maintain efficacy; because effects depend on sustained NAD+ elevation, cycling would mainly produce periods of baseline levels.
  • Stopping triggers: a new Parkinson’s or cancer diagnosis, pregnancy with intake above 230 mg/day, or a homocysteine rise are common-practice reasons to stop.

Sourcing and Quality

  • NR chloride: the form used in nearly all human trials, sold as Niagen by ChromaDex (now Niagen Bioscience); it is the form covered by the FDA GRAS letter (GRN 000635) and the EU novel-food authorization (Regulation (EU) 2020/16).
  • NR malate and other salts: sold by some brands (e.g., Thorne) with far less human trial data; equivalence to NR chloride is assumed rather than shown.
  • Stability: NR chloride is fairly shelf-stable at room temperature, with shelf life extended in cold storage (FoundMyFitness); heat and moisture degrade NR to nicotinamide.
  • Third-party testing: independent verification (USP, NSF or ConsumerLab, which are independent certification or testing bodies) confirms the labeled NR content and absence of contaminants, which matters because degraded product delivers nicotinamide instead.
  • Reputable brands: Tru Niagen (Niagen Bioscience), Life Extension NAD+ Cell Regenerator (uses Niagen), Thorne NiaCel, and Elysium Basis (NR with pterostilbene) are widely used; combination products deserve scrutiny of added ingredients.
  • Injectable forms: injectable NR has been tested only in small, unpublished safety studies (e.g., NCT07251608; registered completion February 2026, no results posted) and is not equivalent to oral supplements.

Practical Considerations

  • Time to effect: blood NAD+ plateaus after about two weeks and brain NAD+ rises within four weeks (Berven, 2026); the walking benefit in leg-artery disease appeared by three months (NICE; McDermott et al., 2024). Most users notice no felt effect.
  • Common pitfalls: treating a rise in blood NAD+ as proof of benefit, stacking several vitamin B3 forms, buying untested products, and overlooking Parkinson’s disease or cancer history.
  • Regulatory status: sold in the US as a dietary supplement, with an FDA no-questions letter for food use (GRN 000635) and EU novel-food authorization up to 300 mg/day (Regulation (EU) 2020/16); it is not an approved drug for any condition.
  • Cost and access: widely available; gram-level trial doses cost several times more than label doses, while plain nicotinamide is far cheaper but has not been tested head-to-head on clinical outcomes.
  • Funding and payer context: as an unreimbursed supplement, insurers have no direct financial stake; much research is funded or supplied by manufacturers (ChromaDex, Elysium Health, Nestlé), alongside public grants.

Interaction with Foundational Habits

  • Sleep: No interaction shown. In long COVID, 2 g/day NR did not change sleep quality versus placebo (Wu, 2025); a dedicated sleep trial (NCT06971224) passed its registered completion date (June 2026) with no results posted. Morning dosing is common practice because no evening data exist.
  • Nutrition: Indirect interaction. Diet supplies NAD+ precursors (tryptophan and niacin from meat, fish and legumes), and NR’s clearance draws on methyl donors, so adequate folate, B12 and choline intake is relevant; taking NR with meals improves tolerability.
  • Exercise: None to potentiating. NR did not add blood-pressure benefit to supervised walking (Lin, 2025) but increased exercise-related formation of acetylcarnitine (a muscle fuel-handling metabolite; Remie, 2020); no blunting of training adaptations has been reported.
  • Stress management: No interaction shown. NR did not change anxiety or depression scores versus placebo in long COVID (Wu, 2025); no human data exist on cortisol or stress-response effects.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes personal reference values: homocysteine and a liver panel, an optional whole-blood NAD+ test, and home blood pressure for anyone taking blood-pressure medication. New tremor, stiffness or slowed movement warrants neurological evaluation before starting, given the Parkinson’s trial findings.

Ongoing monitoring follows this cadence: NAD+ and homocysteine at 4–8 weeks after starting or after any dose increase, since NAD+ plateaus by about two weeks (Berven, 2026); then every 6–12 months while taking 1 g/day or more, with liver enzymes at the same visits. At label doses, annual checks alongside routine bloodwork are common practice. Success is defined by tolerability and by the specific outcome sought, such as walking distance, rather than by NAD+ alone.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Whole-blood NAD+ No established target; track the rise from the individual’s own baseline Expected to change; confirms absorption Rose 142% above baseline at 1 g/day (Conze et al., 2019); commercial dried-blood-spot assays are not standardized; fasting morning sample before the daily dose
Homocysteine About 5–15 µmol/L (standard reference range) Safety check; a rise prompts dose reduction Rose slightly at 3 g/day (Berven et al., 2023); fasting sample; pair with folate and B12
ALT and AST Laboratory-specific upper limit, typically about 40–55 U/L (standard reference range) Safety check; a rise prompts stopping ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes; trended upward in Werner syndrome (Shoji et al., 2025); avoid testing after heavy exercise
Home blood pressure (if on antihypertensives) No established target for NR use; track change from the individual’s own baseline Safety check; a drop with light-headedness prompts review Seated morning readings several times weekly for the first month; NR’s own effect is unconfirmed (Martens et al., 2018)

Qualitative markers:

  • Energy levels and fatigue, compared with the pre-supplement baseline
  • Digestive tolerance (diarrhea, nausea, bloating)
  • Walking capacity, such as distance or ease on a fixed route
  • Sleep quality
  • New motor symptoms such as tremor, stiffness or slowed movement

Emerging Research

  • NADage frailty trial: NCT06208527; phase 2, 100 frail adults aged 75 and older, 2 g/day for one year; primary endpoint gait speed in the six-minute walk; recruiting. A positive result would give the first clinical-function evidence in late-life decline; a null result would weaken the longevity rationale.
  • NICE-PAD II: NCT07782671; phase 3, 250 people with leg-artery disease, 1 g/day (ChromaDex-supplied) for six months; six-minute walk; not yet recruiting. A positive result would replicate the main clinical signal; a null result would remove it.
  • Blood pressure and arterial stiffness: NCT03821623; phase 2, 118 middle-aged and older adults with elevated systolic pressure, three months; active, not recruiting. A positive result would confirm the 2018 signal (Martens et al., 2018); a null result would close it.
  • N-AD Alzheimer’s trial: NCT07741071; phase 2, 270 patients, 2 g/day for two years; dementia severity scale; recruiting. A positive result would revive neuroprotection; a null or negative result would reinforce the Parkinson’s concern.
  • Older veterans functional capacity: NCT04691986; 74 participants, 12 weeks; oxygen uptake, strength and gait speed. Primary completion (March 2026) has passed; active, not recruiting, no results posted. Positive or null results would strengthen or weaken the physical-function item.
  • NOPARK completed: NCT03568968 completed June 2025; published results showed worse Parkinson’s scores with NR (Brakedal et al., 2026), now reflected in the benefit and risk items.
  • Gut-microbe mechanism: a Nestlé-funded study suggests NR acts partly via bacterial conversion to nicotinic acid (Christen et al., 2026); confirmation could make cheaper B3 forms equivalent and weaken NR’s distinct case.
  • Vitamin B3 end-products and heart risk: studies measuring 4PY and cardiac outcomes under NR would test the concern raised by Ferrell et al., 2024, which could weaken the safety case.
  • Cancer safety: the mouse metastasis finding (Maric et al., 2023) has no human follow-up; long-term cancer surveillance in large trials could confirm or dispel it.

Conclusion

Nicotinamide riboside is a vitamin B3 supplement that reliably raises the body’s supply of a molecule cells use for energy and repair. What remains unsettled is whether raising this molecule improves health in people who are already healthy.

Across a decade of human trials, most measured outcomes, including blood-sugar control, muscle function, memory, fatigue and blood pressure, did not improve compared with placebo. The few encouraging signals, such as longer walking distance in people with narrowed leg arteries and less airway inflammation in chronic lung disease, come from single trials that have not yet been repeated. Animal evidence for longer life is mixed, and the most rigorous mouse testing found no effect.

Short-term safety at common doses looks reassuring, with mostly mild digestive complaints. Two concerns stand out: the largest and longest trial found modestly faster worsening in early Parkinson’s disease, and laboratory and population data raise open questions about cancer growth and heart risk from vitamin B3 breakdown products.

Much of the evidence was funded, supplied or co-written by companies that sell the supplement, chiefly ChromaDex (now Niagen Bioscience), along with Elysium Health and Nestlé, and the published literature has tended to overstate effects.

For health-focused adults willing to invest in their longevity, the current evidence presents nicotinamide riboside as a well-tolerated way to raise a biological marker, with benefits for healthy aging still unproven and specific risks in certain conditions.

Top - Benefits - Risks - Protocol